QuantX Biosciences has closed an oversubscribed Series B financing round raising USD 85 million. The round was co-led by Lilly Asia Ventures and Sanofi Ventures, with participation from Hongshan and existing investors. QuantX is a computational drug discovery company that uses advanced modelling and high-performance computing to accelerate the design of oral small-molecule therapies. The proceeds will support the clinical development of its best-in-class oral STAT6 and IL-17 inhibitors and advance other programs in immunology and inflammation.

Founded in 2022, QuantX focuses on integrating physics-based and statistical modelling to rapidly identify and optimise drug candidates. The company, previously incubated by OrbiMed and Creacion Ventures, has now raised a cumulative total of USD 130 million. The funds will be used to advance multiple assets towards clinical trials and expand the company's pipeline of first-in-class and best-in-class oral therapies for immune-mediated diseases.

PharmCube's NextBiopharm® database shows that QuantX's STAT6 project trails behing Pfizer and Sanofi's candidates, which are already in human trials. Click here to request a free trial for NextBiopharm®.